EP Patent

EP4161912A1 — Preparation of highly pure amorphous dapagliflozin

Assigned to KRKA dd · Expires 2023-04-12 · 3y expired

What this patent protects

A novel and improved process for the preparation of amorphous dapagliflozin is disclosed. The present invention further provides pharmaceutical compositions containing amorphous dapagliflozin, optionally in a combination with one or more other active substances and methods for ma…

USPTO Abstract

A novel and improved process for the preparation of amorphous dapagliflozin is disclosed. The present invention further provides pharmaceutical compositions containing amorphous dapagliflozin, optionally in a combination with one or more other active substances and methods for making the same.

Drugs covered by this patent

Patent Metadata

Patent number
EP4161912A1
Jurisdiction
EP
Classification
—
Expires
2023-04-12
Drug substance claim
No
Drug product claim
No
Assignee
KRKA dd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.